Examining LKB1 status as a biomarker for response of lung cancer to metformin
Metformin is an FDA-approved drug for the treatment of diabetes. Dr. Edward Gabrielson and his colleagues have found that a gene called LKB1 is altered in 40% of lung cancer patients. He is studying whether lung cancer cells with mutations in LKB1 are sensitive to metformin. His ultimate goal is to use an already-approved drug for the treatment of LKB1-positive lung cancers.